The daraxonrasib pancreatic cancer treatment received U.S. Food and Drug Administration approval on August 26 for advanced disease.
Daraxonrasib, sold under the brand name Rasonque by Revolution Medicines, targets mutated KRAS proteins, which the source says drive tumour growth in more than 90% of pancreatic cancer cases.
In a manufacturer-funded trial involving 500 patients with metastatic pancreatic cancer that had resisted previous therapies, median survival reached 13.2 months with daraxonrasib compared with 6.7 months for patients receiving chemotherapy.
The source said the FDA approved the drug more than six months earlier than expected under a priority review programme intended to accelerate the approval of treatments addressing significant public health needs.
Read: OncoSil FDA Approval Opens US Path for Bile Duct Cancer
Pancreatic cancer is often diagnosed after it has spread. The American Cancer Society figures project more than 67,000 U.S. cases and over 52,000 deaths this year, with a five-year survival rate of 13%.
Reported common side effects of daraxonrasib include rash, diarrhoea, mouth sores and nausea.
